Antibody-Drug Conjugates
•41 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (41)
%
| Company | Market Cap | Price |
|---|---|---|
|
Elahere and Teliso-V are antibody-drug conjugates (ADC), a core platform AbbVie uses in oncology.
|
$431.71B |
$236.56
-1.80%
|
|
AstraZeneca highlights its Antibody Drug Conjugate (ADC) platform with multiple ADC programs (e.g., Enhertu) and P-Sam in development.
|
$262.04B |
$84.53
-1.28%
|
|
Antibody-Drug Conjugates (ADCs) are a key targeted therapy modality in Merck's pipeline via collaborations.
|
$200.78B |
$79.96
-0.16%
|
|
Trodelvy is an antibody-drug conjugate (ADC), a core modality in Gilead's oncology portfolio.
|
$145.76B |
$117.18
-0.40%
|
|
Pfizer leverages Antibody-Drug Conjugates (ADCs), including assets from the Seagen acquisition.
|
$137.19B |
$24.09
-0.15%
|
|
GSK portfolios in Oncology include Antibody-Drug Conjugates (Blenrep, GSK-227, GSK-584), fitting the Antibody-Drug Conjugates tag.
|
$88.43B |
$21.73
|
|
Genmab's pipeline includes Antibody-Drug Conjugates (e.g., Rina-S), a core ADC platform business.
|
$21.05B |
$31.81
-0.28%
|
|
Genmab develops Antibody-Drug Conjugates (e.g., Rina-S in ProfoundBio’s pipeline; Tivdak is an ADC), a major product class for the company.
|
$19.49B |
$315.00
|
|
XB010, XB371, and XB628 represent antibody-drug conjugates in Exelixis’ pipeline, a key biologics modality the company develops.
|
$10.40B |
$38.15
-1.34%
|
|
Antibody-Drug Conjugates-style approach via antibody-oligonucleotide conjugates.
|
$5.18B |
$42.95
+3.74%
|
|
ADClonics platform supports antibody-drug conjugates development in collaboration framework.
|
$4.71B |
$69.05
+1.40%
|
|
Zai Lab is advancing antibody-drug conjugates (e.g., ZL-1310, ZL-6201) as a key platform in its oncology pipeline.
|
$3.43B |
$31.62
+0.86%
|
|
TLX591 is an antibody-based PSMA therapeutic, aligning with Antibody-Drug Conjugates as a modality category.
|
$3.35B |
$10.00
|
|
IDEAYA's lead program IDE849 is an antibody-drug conjugate targeting DLL3, aligning with Antibody-Drug Conjugates.
|
$2.30B |
$26.24
-2.42%
|
|
Next-generation Antibody Drug Conjugates (ADC) assets such as BHV-1510 with a novel payload.
|
$1.61B |
$15.80
-9.97%
|
|
Zymeworks directly develops and licenses Antibody-Drug Conjugates (ADCs), including zanidatamab and WHOLLY-OWNED ADCs like ZW191, ZW251, and ZW220.
|
$1.26B |
$18.06
+4.39%
|
|
Antibody-Drug Conjugates (ADCs) are a core direct product/technology focus (IM-1021) and a major investable category for Immunome.
|
$1.21B |
$13.92
-5.18%
|
|
DAY301 is an Antibody-Drug Conjugate, representing a separate major product modality in the pipeline.
|
$733.86M |
$7.24
-3.34%
|
|
Antibody-Drug Conjugates as a key therapeutic modality under development.
|
$685.29M |
$22.51
-1.01%
|
|
ARR-217 is an Antibody-Drug Conjugate program licensed and developed by ArriVent, representing a distinct ADC product category.
|
$678.78M |
$19.84
+5.42%
|
|
ABC Platform enables antibody biopolymer conjugates (antibody-based conjugates) used for durable ocular therapies.
|
$626.30M |
$11.87
-11.42%
|
|
Antibody-drug/conjugate modality framework via MNPR-101 platform and payloads.
|
$537.04M |
$87.82
-14.34%
|
|
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), a core direct product the company sells.
|
$404.65M |
$4.36
+6.86%
|
|
CX-2051 is an EpCAM-directed PROBODY ADC, directly making Antibody-Drug Conjugates.
|
$266.05M |
$3.30
+1.23%
|
|
Lead asset MICVO is an antibody-drug conjugate (ADC).
|
$229.21M |
$3.70
-3.39%
|
|
CRB-701 is a next-generation antibody-drug conjugate targeting Nectin-4 for solid tumors.
|
$190.16M |
$15.54
-2.08%
|
|
IPH4502 is Innate Pharma's proprietary Antibody-Drug Conjugate targeting Nectin-4, a directly produced product.
|
$164.36M |
$2.03
+2.53%
|
|
ADC-focused pipeline (MGC026, MGC028, vobra duo) using novel TOP1i payloads.
|
$106.62M |
$1.69
-4.52%
|
|
ALXO's lead and preclinical programs include antibody-drug conjugates (ADC), notably ALX2004 and evorpacept-based combos.
|
$99.94M |
$1.76
-5.88%
|
|
Plans/develops antibody-drug conjugates (ADCs) via its platform for oncology.
|
$86.33M |
$1.95
-1.52%
|
|
Developing Antibody-Drug Conjugates (precision ADCs) including CALR-targeted formats and collaborations.
|
$71.14M |
$1.26
-9.35%
|
|
Direct product category: Antibody-Drug Conjugates (ADC) therapies, including next-generation ADC programs.
|
$67.88M |
$0.80
-5.80%
|
|
OST-tADC represents an antibody-drug conjugate platform, a major product modality for targeted cancer therapy.
|
$55.91M |
$1.99
-5.24%
|
|
AKTX develops Antibody-Drug Conjugates (AKTX-101, AKTX-102) including novel payloads, targeting Trop2, i.e., direct ADC product category.
|
$50.76M |
$1.02
+11.90%
|
|
Ozuriftamab vedotin (Oz-V) and Mecbotamab vedotin (Mec-V) are antibody-drug conjugates, a core ADC program under the CAB platform.
|
$50.68M |
$0.87
-17.38%
|
|
Actimab-A combines an antibody with a radioactive payload, fitting antibody-drug conjugate (ADC)-style technology in oncology.
|
$46.48M |
$1.49
-1.97%
|
|
Emi-Le (XMT-1660) is an antibody-drug conjugate (ADC) using the Dolasynthen platform.
|
$46.06M |
$9.24
+1.43%
|
|
FG-3246 is an antibody-drug conjugate (ADC) targeting CD46 for oncology.
|
$42.64M |
$10.55
-3.74%
|
|
NXTC directly develops and pursues Antibody-Drug Conjugates (ADCs) as its lead oncology therapies (LNCB74, SIM0505).
|
$15.54M |
$6.65
+5.59%
|
|
ISACs are antibody-drug conjugate-like immune-stimulating antibody conjugates, a major cancer immunotherapy modality.
|
$11.12M |
$5.80
-1.60%
|
|
CBIO's lead and pipeline ADC programs (CR-002, CR-003) are antibody-drug conjugates, a distinct major product modality.
|
$7.32M |
$11.35
-6.81%
|
Loading industry metrics...
Loading comparison data...
